Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma

Best Practice and Research: Clinical Haematology

Volumn 19, Issue 4, 2006, Pages 669-684

  Inwards, David J ^a   Cilley, Jeffrey C ^b   Winter, Jane N ^c  

^a Mayo Clinic College of Medicine   (United States)

^b NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

autologous stem cell transplantation; I 131 tositumomab; non Hodgkin lymphoma; radioimmunotherapy; yttrium 90 ibritumomab tiuxetan

Indexed keywords

CARMUSTINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IBRITUMOMAB TIUXETAN; INDIUM 111; INTERFERON; IODINE 131; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; MONOCLONAL ANTIBODY CD37; POTASSIUM IODIDE; RADIOPHARMACEUTICAL AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; THIOTEPA; THYROXINE; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE; YTTRIUM 90;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG FEVER; DRUG MEGADOSE; FATIGUE; FOLLICULAR LYMPHOMA; HUMAN; HYPOTHYROIDISM; INFECTION; LUNG TOXICITY; LYMPHOMA; MANTLE CELL LYMPHOMA; MYELOABLATIVE CONDITIONING; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; TREATMENT FAILURE; WHOLE BODY RADIATION;

DOSE-RESPONSE RELATIONSHIP, RADIATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCONJUGATES; LYMPHOMA; RADIOIMMUNOTHERAPY; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 33748887297     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2006.05.004     Document Type: Review

References (50)

1. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [see comment]. The New England Journal of Medicine 346 4 (2002) 235-242
2. Habermann T.M., Weller E.A., Morrison V.A., et al. Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLDCL). Blood 102 11 (2003) 6a
3. Vose J.M., Link B.K., Grossbard M.L., et al. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leukemia & Lymphoma 46 11 (2005) 1569-1573
4. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. [see comment]. The New England Journal of Medicine 333 23 (1995) 1540-1545
5. Hahn T., Wolff S.N., Czuczman M., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review. Biology of Blood and Marrow Transplantation 7 6 (2001) 308-331
6. Mac Manus M.P., and Hoppe R.T. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 14 4 (1996) 1282-1290
7. Seymour J.F., Pro B., Fuller L.M., et al. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 21 11 (2003) 2115-2122
8. Hiddemann W., Kneba M., Dreyling M., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106 12 (2005) 3725-3732
9. Rohatiner A.Z., Gregory W.M., Peterson B., et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23 10 (2005) 2215-2223
10. Hochster H.S., Weller E., Ryan T., et al. Results of E1496: a phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 22 14_supplement (2004) 6502 (Meeting Abstracts)
11. Schouten H.C., Qian W., Kvaloy S., et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. [see comment]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 21 21 (2003) 3918-3927
12. van Besien K., Loberiza Jr. F.R., Bajorunaite R., et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102 10 (2003) 3521-3529
13. Romaguera J.E., Fayad L., Rodriguez M.A., et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23 28 (2005) 7013-7023
14. Vose J.M., Bierman P.J., Weisenburger D.D., et al. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biology of Blood and Marrow Transplantation 6 6 (2000) 640-645
15. Dreyling M., Lenz G., Hoster E., et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105 7 (2005) 2677-2684
16. Ganti A.K., Bierman P.J., Lynch J.C., et al. Hematopoietic stem cell transplantation in mantle cell lymphoma. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 16 4 (2005) 618-624
17. Press O.W. Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective. Seminars in Oncology 30 2 supplement 4 (2003) 10-21
18. Kaminski M.S., Fig L.M., Zasadny K.R., et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 10 11 (1992) 1696-1711
19. Juweid M., Sharkey R.M., Markowitz A., et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Research 55 23 supplement (1995) 5899s-5907s
20. Witzig T.E., White C.A., Wiseman G.A., et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17 12 (1999) 3793-3803
21. Witzig T.E., Flinn I.W., Gordon L.I., et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 20 15 (2002) 3262-3269
22. Kaminski M.S., Zasadny K.R., Francis I.R., et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. The New England Journal of Medicine 329 7 (1993) 459-465
23. Kaminski M.S., Estes J., Zasadny K.R., et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96 4 (2000) 1259-1266
24. Evens A.M., and Gordon L.I. Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond. Clinical Lymphoma 5 supplement 1 (2004) S11-S15
25. Vose J.M. Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Oncologist 9 2 (2004) 160-172
26. Knox S.J., Levy R., Miller R.A., et al. Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Research 50 16 (1990) 4935-4940
27. Kaminski M.S., Zasadny K.R., Francis I.R., et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 14 7 (1996) 1974-1981
28. Vose J.M., Wahl R.L., Saleh M., et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18 6 (2000) 1316-1323
29. Kaminski M.S., Zelenetz A.D., Press O.W., et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. [see comment]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 19 19 (2001) 3918-3928
30. Kaminski M.S., Tuck M., Estes J., et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. [see comment]. The New England Journal of Medicine 352 5 (2005) 441-449
31. Kaminski M.S., Radford J.A., Gregory S.A., et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23 31 (2005) 7985-7993
32. Witzig T.E. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. Drugs of Today (Barcelona, Spain: 1998) 40 2 (2004) 111-119
33. Knox S.J., Goris M.L., Trisler K., et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 2 3 (1996) 457-470
34. Witzig T.E., Gordon L.I., Cabanillas F., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 20 10 (2002) 2453-2463
35. Witzig T., Wiseman G., Geyer S., et al. A phase I trial of two-sequential doses of ZevalinTM radioimmunotherapy for relapsed low-grade B-cell non-Hodgkin's lymphoma. Blood 102 11 (2003) 406a
36. Press O.W., Eary J.F., Appelbaum F.R., et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. [see comment]. The New England Journal of Medicine 329 17 (1993) 1219-1224
37. Press O.W., Eary J.F., Appelbaum F.R., et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346 8971 (1995) 336-340
38. Liu S.Y., Eary J.F., Petersdorf S.H., et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 16 10 (1998) 3270-3278
39. Gopal A.K., Rajendran J.G., Gooley T.A., et al. A Phase II Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥60 Years of Age with High-Risk Relapsed or Refractory B-Cell Lymphoma. ASH Annual Meeting Abstracts 106 11 (2005) 487
40. Flinn I.W., Kahl B.S., Frey E., et al. Dose Finding Trial of Yttrium 90 (90Y) Ibritumomab Tiuxetan with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). ASH Annual Meeting Abstracts 104 11 (2004) 897
41. Vanazzi A., Ferrucci P., Ferrari M., et al. High Dose Zevalin (90Yttrium Ibritumomab Tiuxetan) Treatment with PBSC Support in Refractory-Resistant NHL Patients: Preliminary Results of a Phase I/II Study. ASH Annual Meeting Abstracts 106 11 (2005) 488
42. Devizzi L., Seregni E., Guidetti A., et al. High-Dose Myeloablative Zevalin Radioimmunotherapy with Tandem Stem-Cell Autografting Has Minimal Toxicity and Full Feasibility in an Outpatient Setting. ASH Annual Meeting Abstracts 106 11 (2005) 2737
43. Press O.W., Eary J.F., Gooley T., et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. [see comment]. Blood 96 9 (2000) 2934-2942
44. Vose J.M., Bierman P.J., Enke C., et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23 3 (2005) 461-467
45. Nademanee A., Krishnan A., Fung H., et al. Yttrium 90 (90Y) ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma (NHL): incorporation into autologous stem cell transplantation (ASCT) regimens. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 16 supplement 5 (2005) 100
46. Winter J., Inwards D., Spies S., et al. Zevalin (90YZ) doses >.5 mci/kg may be combined with high-dose BEAM and autotransplant (ASCT). Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 16 supplement 5 (2005) 100
47. Nademanee A., Forman S., Molina A., et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106 8 (2005) 2896-2902
48. Gopal A.K., Gooley T.A., Maloney D.G., et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. [see comment]. Blood 102 7 (2003) 2351-2357
49. Gopal A.K., Rajendran J.G., Petersdorf S.H., et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99 9 (2002) 3158-3162
50. Krishnan A., Raubitschek A., Forman S.J., et al. New Transplant Strategies Utilizing Radioimmunotherapy (RIT) Based Regimens To Reduce Relapse in High Risk Mantle Cell Lymphoma (MCL). ASH Annual Meeting Abstracts 106 11 (2005) 681